Fig. 1 · Structure

Documents & Downloads

Paclitaxel

Cat. No. A10689 CAS 33069-62-4

Microtubule Associated inhibitor

Paclitaxel (Taxol) is a mitotic inhibitor that stabilizes microtubules and as a result, interferes with the normal breakdown of microtubules during cell division.

In Stock

Publications for Paclitaxel

11 publications citing this product

  1. Onyinyechi Obidiro, .et al. , Journal of Biomedical Nanotechnology, 2026, 22(1):47-69 PMID: 42518749
  2. Ramisa Fariha, .et al. , Micromachines (Basel), 2026, Mar 9;17(3):332 PMID: 41900218
  3. Seungyeon Ryu, .et al. , Breast Cancer Res, 2025, Jun 23;27(1):113 PMID: 40551232
  4. Kai-Yue Cao, .et al. , Noncoding RNA Res, 2024, Nov 12;11:38-47 PMID: 39736854
  5. Laura Svajda, .et al. , Biomed Pharmacother, 2024, Nov:180:117601 PMID: 39476764
  6. Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138
  7. Yu Pan, .et al. , Nucleic Acids Res, 2021, Jan 11;49(1):38-52 PMID: 33290562
  8. Li-Li Li, .et al. , Nat Commun, 2020, Oct 9;11(1):5107 PMID: 33037199
  9. Baglo Y, .et al. , Photochem Photobiol, 2019, Dec 19 PMID: 31856423
  10. Owiti AO, .et al. , AAPS PharmSciTech, 2018, Nov;19(8):3534-3549 PMID: 30151731

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Paclitaxel suppresses microtubule dynamic instability. In a purified bovine-brain tubulin assay, 250 nM paclitaxel reduced microtubule shortening rate by 51% and overall dynamicity by 40% relative to vehicle. Growth rate and catastrophe frequency were not significantly changed under these conditions. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Microtubule (human endothelial cells) 0.1 pM

Cellular Effect

Cell Line Activity Value Description Reference
143B IC50 5.56 μM Antiproliferative activity against human 143B cells after 48 hrs by MTT assay [PMID: 29223717]
184B5 IC50 2.32 μM Antiproliferative activity against human 184B5 cells after 72 hrs by SRB assay [PMID: 26602827]
1A9 ED50 0.001 μg/mL Cytotoxicity against human 1A9 cells by sulforhodamine B assay [PMID: 17643301]
1A9 ED50 0.002 μg/mL Cytotoxicity against human 1A9 cells after 3 days by SRB assay [PMID: 14640511]
1A9 IC50 0.002 μM Cytotoxicity against human 1A9 cells after 3 days by SRB assay [PMID: 16038545]
1A9 ED50 0.041 μg/mL Cytotoxicity against human 1A9 cells after 6 days by SRB assay [PMID: 14640511]
1A9 GI50 0.71 nM Growth inhibition of human 1A9 cells after 72 hrs [PMID: 17542572]
1A9 ED50 1 nM Cytotoxicity against human 1A9 cells by sulforhodamine B assay [PMID: 17350834]
1A9 ED50 2.09 nM Antiproliferative activity against human 1A9 cells after 3 days by sulforhodamine B assay [PMID: 21296579]
1A9 IC50 21.5 nM Inhibition of growth in epothilone A resistant 1A9-A8 T-beta-274I mutant cell line after 72 hrs by SRB assay [PMID: 17263521]
1A9 IC50 3.9 nM Cytotoxicity against human 1A9 cells by MTT assay [PMID: 25047938]
1A9 IC50 4.8 nM Inhibition of growth in 1A9 cell line after 72 hrs [PMID: 17263521]
1A9 GI50 5.2 nM Induction of microtubule stabilization in human 1A9 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter reagent-based assay [PMID: 31191870]
1A9/ptx-10 IC50 157 nM Inhibition of growth in paclitaxel resistant 1A9-PTX10 F-beta-270V mutant cell line after 72 hrs by SRB assay [PMID: 17263521]
1A9/ptx-10 IC50 532.95 nM Cytotoxicity against paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin after 72 hrs [PMID: 19239240]
1A9/ptx-10 IC50 532.95 nM Cytotoxicity against paclitaxel resistant human 1A9PTX10 cells expressing class 1 beta-tubulin mutant after 72 hrs [PMID: 18465846]
1A9/ptx-10 GI50 64 nM Growth inhibition of beta tubulin Phe270Val mutant expressing human 1A9/Ptx10 cells after 72 hrs [PMID: 17542572]
1A9/ptx-10 IC50 81.4 nM Cytotoxicity against human 1A9PTX10 cells by MTT assay [PMID: 25047938]
1A9/ptx-22 IC50 160.7 nM Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells harboring point mutation in beta-tubulin after 72 hrs [PMID: 19239240]
1A9/ptx-22 IC50 160.7 nM Cytotoxicity against paclitaxel resistant human 1A9PTX22 cells expressing class 1 beta-tubulin mutant after 72 hrs [PMID: 18465846]

20 records · Scroll to view more

Paclitaxel Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Paclitaxel from 3 published references. In vitro models include Caov-3 ovarian adenocarcinoma and A-498 kidney carcinoma cells.

Paclitaxel In Vitro Studies

Paclitaxel responses differed between human cancer cell lines. After 4 h exposure, 30 nM in Caov-3 ovarian cells and 100 nM in A-498 kidney cells reduced interphase microtubule dynamicity by 31% and 63%, respectively. In a separate 24 h proliferation assay, 30 nM completely inhibited Caov-3 live-cell accumulation, whereas 100 nM inhibited A-498 accumulation by 72.1%. Proliferation inhibition is distinct from the fraction of cells killed. [2]

Paclitaxel suppresses purified microtubule dynamics

Biochemical assay · Phosphocellulose-purified, MAP-free bovine brain tubulin (17 μM), assembled from axoneme seeds [1]

At 250 nM paclitaxel, shortening and overall dynamicity decreased relative to ethanol vehicle; growth rate and catastrophe frequency were not significantly changed. Taccalonolide AJ was a separate comparator, not a combination treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Microtubule plus-end shortening ratemean ± SEM Vehicle 11.9 ± 1; 250 nM PTX 5.8 ± 0.4 μm/min; −51%; P < 0.001[1]
Overall microtubule dynamicitydynamicity Vehicle 2.73; 250 nM PTX 1.63 μm/min; −40%[1]
Growth rate and catastrophe frequencymean ± SEM Growth rate: 2.7 ± 0.2 to 2.8 ± 0.2 μm/min; catastrophe: 0.28 ± 0.05 to 0.26 ± 0.04 per min; neither marked significant[1]

Literature-Reported Treatment Conditions

Treatment concentration
250 nM paclitaxel
Exposure duration
30 min to steady state at 35°C; 10 min real-time recordings
Method
Single-agent exposure; see model-specific methods.
Vehicle
Ethanol vehicle
Reported limits
No Adooq lot tested; supplier material identity is as reported, without independent stereochemical or purity verification.
Methods and source locations

Compound reported in the paper: Paclitaxel (Taxol); Compound label in the paper: paclitaxel

Parent-compound research evidence; no supplier or lot equivalence claim.

Table 1 (vehicle and 250 nM PTX columns and footnotes); Results, purified-tubulin dynamics; Methods, Materials and Microtubule dynamic instability with phosphocellulose purified tubulin

Microtubule plus-end shortening rate: Differential interference contrast microscopy; approximately 25 microtubules per condition in table footnote; Student’s t-test. — Table 1, Shortening rate row

Overall microtubule dynamicity: Microtubule tracking; table gives no error estimate for dynamicity. — Table 1, Dynamicity row

Growth rate and catastrophe frequency: Vehicle versus 250 nM PTX; absence of statistical significance is not proof of equivalence. — Table 1, Growth rate and Catastrophe frequency rows; Results comparison paragraph

Microtubule dynamics in living ovarian and kidney cancer cells

Cell-based study · Caov-3 human ovarian adenocarcinoma and A-498 human kidney carcinoma cells [2]

Paclitaxel reduced growth and shortening rates and overall dynamicity in both cell lines at different extracellular concentrations. A-498 pause duration increased significantly; Caov-3 pause duration did not. These measurements concern peripheral interphase microtubules, not direct tracking of spindle microtubules.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Overall dynamicitydynamicity Caov-3: control 3.13, treated 2.17 μm/min (−31%); A-498: control 3.01, treated 1.12 μm/min (−63%)[2]
Microtubule growth ratemean ± SD Caov-3: 8.27 ± 4.5 to 6.30 ± 3.7 μm/min (−24%, 99% confidence); A-498: 8.36 ± 4.2 to 6.83 ± 4.0 μm/min (−18%, 95% confidence)[2]
Pause durationmean ± SD A-498: 12.78 ± 13.6 to 22.29 ± 18.3 s (99.9% confidence); Caov-3: 14.5 ± 15.6 to 16.9 ± 16.5 s (not significant)[2]

Literature-Reported Treatment Conditions

Treatment concentration
Caov-3: 30 nM; A-498: 100 nM added to culture medium
Exposure duration
4 h exposure; dynamics recorded for 0–2 h afterward in medium lacking taxol
Method
Single-agent exposure; see model-specific methods.
Vehicle
10 mM stock in methanol, intermediate dilution in PIPES buffer; final methanol fraction not stated
Reported limits
No Adooq lot tested; supplier material identity is as reported, without independent stereochemical or purity verification.
Methods and source locations

Compound reported in the paper: Paclitaxel (Taxol); Compound label in the paper: taxol

Parent-compound research evidence; no supplier or lot equivalence claim.

Tables 1–3; Results, Microtubule Dynamics in Untreated Caov-3 Ovarian Tumor Cells and A-498 Kidney Tumor Cells through Taxol Reduced Dynamicity; Materials and Methods, Materials and dynamics analysis

Overall dynamicity: Quantitative fluorescence video microscopy after rhodamine-tubulin microinjection. Microtubules: Caov-3 36 control/34 treated; A-498 40 control/26 treated; counts are not independent experiments. — Table 3, Dynamicity and Number of microtubules rows

Microtubule growth rate: Student’s t-test as reported; control versus treated. — Table 2, Growth rate row and significance footnotes

Pause duration: Reported lack of significant change retained for Caov-3. — Table 3, Pause duration row and footnotes; Results, Taxol Increased the Duration and Percentage of Time in the Paused State

Paclitaxel inhibits proliferation with cell-line-dependent sensitivity

Cell-based study · Caov-3 ovarian adenocarcinoma and A-498 kidney carcinoma cells [2]

At 24 h, 30 nM taxol completely inhibited Caov-3 proliferation, whereas 100 nM inhibited A-498 proliferation by 72.1%. The endpoint is net live-cell accumulation relative to untreated parallel cultures, not a direct fraction of cells killed.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of live-cell accumulationproliferation inhibition Caov-3: complete inhibition at 30 nM; A-498: 72.1% inhibition at 100 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration series; representative reported exposures: Caov-3 30 nM and A-498 100 nM
Exposure duration
24 h
Method
Single-agent exposure; see model-specific methods.
Vehicle
Methanol stock with buffer intermediate dilution; final solvent fraction not stated
Reported limits
No Adooq lot tested; supplier material identity is as reported, without independent stereochemical or purity verification.
Methods and source locations

Compound reported in the paper: Paclitaxel (Taxol); Compound label in the paper: taxol

Parent-compound research evidence; no supplier or lot equivalence claim.

Figure 1 and caption; Results, Low Concentrations of Taxol Inhibit Proliferation; Methods, Cell Culture and Proliferation and Materials

Inhibition of live-cell accumulation: Hemocytometer live-cell counts at addition and 24 h, compared with parallel taxol-free culture. Figure values are means and SEs of 4 independent Caov-3 experiments and 11 independent A-498 experiments. Values >100% indicate net cell loss. — Results, Low Concentrations of Taxol Inhibit Proliferation; Figure 1 and caption

Paclitaxel In Vivo Studies

In HT-1080 xenografts in nude mice, a single intravenous 30 mg/kg bolus of injectable paclitaxel produced mitotic arrest followed by slippage and multinucleation. The tumor mitotic index peaked at approximately 7% at 24 h, compared with approximately 75% in a separate cultured-cell experiment using 100 nM paclitaxel. These model-specific observations show that cellular responses in tumors can differ substantially from those in culture. [3]

Mitotic arrest and slippage in an HT-1080 xenograft

Animal study · HT-1080 human tumor xenografts in dorsal skinfold chambers in Nu/Nu (Cox-7) mice; fluorescent histone-H2b imaging [3]

After a single 30 mg/kg intravenous bolus of formulated paclitaxel, intravital imaging showed mitotic arrest, slippage and persistent multinucleated cells. The peak tumor mitotic index was much lower than in cultured HT-1080 cells. This is a pharmacodynamic imaging study, not evidence that every responding tumor cell dies during mitotic arrest.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mitotic index over timemitotic index Tumor: ~1% before treatment, ~7% peak at 24 h, zero at 168 h; cultured cells: ~75% peak at 24 h with 100 nM paclitaxel[3]
Cell fate after mitotic arrestqualitative imaging Imaged cells slipped from arrest and persisted as multinucleated cells; some multinucleated cells subsequently died[3]

Conditions shared by the study groups

Route
Intravenous, tail vein
Frequency
Single bolus
Treatment course
One administration; follow-up to 168 h for Figure 3 indices
Vehicle
Novaplus injectable formulation diluted 1:4 with saline; stock excipient composition not specified in the acquired Methods
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Paclitaxel 30 mg/kgPre-paclitaxel tumor baseline; separate culture comparator at 100 nMAfter a single 30 mg/kg intravenous bolus of formulated paclitaxel, intravital imaging showed mitotic arrest, slippage and persistent multinucleated cells. The peak tumor mitotic index was much lower than in cultured HT-1080 cells. This is a pharmacodynamic imaging study, not evidence that every responding tumor cell dies during mitotic arrest.[3]
Paclitaxel 30 mg/kg
Model: HT-1080 human tumor xenografts in dorsal skinfold chambers in Nu/Nu (Cox-7) mice; fluorescent histone-H2b imaging
Reported limits: Mouse sex, age and Figure 3 mouse n not specified in acquired main text; injectable stock excipient composition not specified.
Methods and source locations

Compound reported in the paper: Paclitaxel (Taxol); Compound label in the paper: paclitaxel

Reported experimental material and conditions only; formulation-specific animal findings cannot establish equivalence of an unformulated catalog product.

Figure 3a–l and caption; Results, High-dose Paclitaxel effects; Methods, Mice and Paclitaxel and Kinesin-5 inhibitor treatment

Mitotic index over time: Over 1000 cells scored in vivo per time point; 240 cells tracked in culture. These are cell counts, not mouse n. Approximations are author-reported; no decimals inferred from bars. — Figure 3k–l and caption; Results, High-dose Paclitaxel effects

Cell fate after mitotic arrest: Time-lapse intravital microscopy; Figure 3 image viewed. No numerical apoptosis fraction inferred. — Figure 3a–j and caption

Paclitaxel 30 mg/kg · Figure 3a–l and caption; Results, High-dose Paclitaxel effects; Methods, Mice and Paclitaxel and Kinesin-5 inhibitor treatment

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 33069-62-4
Applications Microtubule Associated inhibitor
Formula C47H51NO14
Molecular Weight 853.9
Synonyms Taxol
SMILES
CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 152 mg/mL (178 mM)
Water Insoluble
Ethanol 16 mg/mL (18.73 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
5 mg/mL
Vehicle
5% DMSO+40% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Paclitaxel Research References

  1. [1] Risinger AL, Riffle SM, Lopus M, et al. The taccalonolides and paclitaxel cause distinct effects on microtubule dynamics and aster formation. Molecular cancer (2014). PMID: 24576146 DOI: 10.1186/1476-4598-13-41 Source material
  2. [2] Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Molecular biology of the cell (1999). PMID: 10198049 DOI: 10.1091/mbc.10.4.947 Source material
  3. [3] Orth JD, Kohler RH, Foijer F, et al. Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer research (2011). PMID: 21712408 DOI: 10.1158/0008-5472.can-11-0412 Source material

Publications

11 publications citing this product

  1. Onyinyechi Obidiro, .et al. , Journal of Biomedical Nanotechnology, 2026, 22(1):47-69 PMID: 42518749
  2. Ramisa Fariha, .et al. , Micromachines (Basel), 2026, Mar 9;17(3):332 PMID: 41900218
  3. Seungyeon Ryu, .et al. , Breast Cancer Res, 2025, Jun 23;27(1):113 PMID: 40551232
  4. Kai-Yue Cao, .et al. , Noncoding RNA Res, 2024, Nov 12;11:38-47 PMID: 39736854
  5. Laura Svajda, .et al. , Biomed Pharmacother, 2024, Nov:180:117601 PMID: 39476764
  6. Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138
  7. Yu Pan, .et al. , Nucleic Acids Res, 2021, Jan 11;49(1):38-52 PMID: 33290562
  8. Li-Li Li, .et al. , Nat Commun, 2020, Oct 9;11(1):5107 PMID: 33037199
  9. Baglo Y, .et al. , Photochem Photobiol, 2019, Dec 19 PMID: 31856423
  10. Owiti AO, .et al. , AAPS PharmSciTech, 2018, Nov;19(8):3534-3549 PMID: 30151731
  11. Owiti AO, .et al. , AAPS PharmSciTech, 2018, Oct;19(7):3110-3122 PMID: 30112614

Showing 10 of 11 publications

Added to your cart

View Cart Checkout
Loading...